Ghost Tree Capital’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$12.1M Sell
135,000
-15,000
-10% -$1.31M 3.66% 6
2024
Q2
$12.1M Sell
150,000
-60,000
-29% -$4.44M 3.78% 6
2024
Q1
$16.8M Buy
210,000
+45,000
+27% +$3.78M 4.64% 2
2023
Q4
$13.1M Buy
165,000
+55,000
+50% +$3.68M 4.29% 5
2023
Q3
$7.69M Hold
110,000
2.53% 10
2023
Q2
$7.9M Sell
110,000
-115,000
-51% -$8.48M 2.61% 14
2023
Q1
$13.9M Sell
225,000
-10,000
-4% -$657K 4.1% 6
2022
Q4
$18.1M Sell
235,000
-65,000
-22% -$3.89M 7.74% 2
2022
Q3
$13.4M Buy
300,000
+75,000
+33% +$3.75M 3.76% 9
2022
Q2
$8.62M Buy
225,000
+130,500
+138% +$4.13M 4.49% 6
2022
Q1
$3.91M Buy
+94,500
New +$2.93M 0.85% 21
2020
Q3
Sell
-100,000
Closed -$8.23M 48
2020
Q2
$8.23M Sell
100,000
-115,000
-53% -$8.85M 2.17% 20
2020
Q1
$12.6M Buy
215,000
+15,000
+8% +$1.22M 3.35% 9
2019
Q4
$20.7M Sell
200,000
-475,000
-70% -$19.2M 3.94% 5
2019
Q3
$13.7M Sell
675,000
-175,000
-21% -$4.5M 3.48% 13
2019
Q2
$21.9M Buy
850,000
+540,000
+174% +$10.8M 4.54% 7
2019
Q1
$4.41M Buy
+310,000
New +$2.88M 1.15% 31

Other funds holding AXSM

Ghost Tree Capital's AXSM Position: Q3 2024 in Review

Ghost Tree Capital reduced its Axsome Therapeutics (AXSM) stake by 10% in Q3 2024, selling an estimated $1.31M and leaving 135,000 shares worth $12.1M. The position accounts for 3.66% of the portfolio, ranked #6.

Ghost Tree Capital first reported a position in AXSM in Q1 2019 and has held it in 17 quarters since. The position peaked at $21.9M in Q2 2019. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Ghost Tree Capital held 135,000 shares of Axsome Therapeutics worth $12.1M as of Q3 2024.
  • Ghost Tree Capital sold 15,000 Axsome Therapeutics shares in Q3 2024, an estimated $1.31M.
  • Axsome Therapeutics made up 3.66% of Ghost Tree Capital's portfolio in Q3 2024, its #6 holding.
  • Ghost Tree Capital first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • Ghost Tree Capital's Axsome Therapeutics position peaked at $21.9M in Q2 2019.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.